Senseonics (SENS) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SENS shares.
View SENS analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 1 year price targets for Senseonics' shares. Their SENS share price forecasts range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 373.0% from the stock's current price.
View analysts price targets for SENS or view top-rated stocks among Wall Street analysts.

Senseonics' stock was trading at $0.8246 on January 1st, 2023. Since then, SENS stock has decreased by 23.1% and is now trading at $0.6342.
View the best growth stocks for 2023 here.

Senseonics Holdings, Inc. (NYSEAMERICAN:SENS) issued its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. The firm had revenue of $5.57 million for the quarter, compared to analysts' expectations of $4.99 million. Senseonics had a trailing twelve-month return on equity of 266.98% and a net margin of 314.37%.

ETFs with the largest weight of Senseonics (NYSEAMERICAN:SENS) stock in their portfolio include Fidelity Digital Health ETF (FDHT), Global X Telemedicine & Digital Health ETF (EDOC), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI),

Senseonics updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $20.00 million-$24.00 million, compared to the consensus revenue estimate of $21.57 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Senseonics investors own include VirnetX (VHC), Advanced Micro Devices (AMD), Micron Technology (MU), Nabriva Therapeutics (NBRV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Tandem Diabetes Care (TNDM), CytoDyn (CYDY), TherapeuticsMD (TXMD).

Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."

Senseonics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.75%), State Street Corp (2.49%), Geode Capital Management LLC (1.84%), Charles Schwab Investment Management Inc. (0.74%), Bank of New York Mellon Corp (0.33%) and AXA S.A. (0.24%). Insiders that own company stock include Anthony R Raab, Douglas A Roeder, Douglas S Prince, Edward Fiorentino, Francine Kaufman, Mirasol Panlilio, Mukul Jain, Nick B Tressler, Stephen P Defalco and Timothy T Goodnow.
View institutional ownership trends.

Shares of SENS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SENS stock can currently be purchased for approximately $0.63.

Senseonics (NYSEAMERICAN:SENS) has a market capitalization of $304.33 million and generates $16.39 million in revenue each year. The company earns $142.12 million in net income (profit) each year or ($0.17) on an earnings per share basis.

Senseonics' mailing address is 20451 Seneca Meadows Pkwy, GERMANTOWN, MD 20876-7005, United States. The official website for the company is www.senseonics.com. The company can be reached via phone at (301) 515-7260, via email at investors@senseonics.com, or via fax at 301-515-0988.